Anti-tumor immunity in a model of acute myeloid leukemia

References

• Cornelissen J J, Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005; 151–155
   PubMedGoogle Scholar
• Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217–1225
   PubMed Web of Science ®Google Scholar
• Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G, Heilmann V, Gschwend J, Bergmann L, Dohner H, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002; 30: 1029–1035
   PubMed Web of Science ®Google Scholar
• Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H, Schmitt M. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003; 106: 224–231
   PubMed Web of Science ®Google Scholar
• Guinn B A, Bland E A, Lodi U, Liggins A P, Tobal K, Petters S, Wells J W, Banham A H, Mufti G J. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 335: 1293–1304
   PubMed Web of Science ®Google Scholar
• Heslop H E, Stevenson F K, Molldrem J J. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program 2003; 331–349
   PubMedGoogle Scholar
• Guinn B A, Gilkes A F, Woodward E, Westwood N B, Mufti G J, Linch D, Burnett A K, Mills K I. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 333: 703–713
   PubMed Web of Science ®Google Scholar
• Granatek C H, Ezaki K, Hersh E M, Keating M J, Rasmussen S. Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy. Cancer 1981; 47: 272–279
   PubMed Web of Science ®Google Scholar
• Guinn B A, Mohamedali A, Thomas N S, Mills K I. Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother 2007; 56: 943–957
   PubMed Web of Science ®Google Scholar
• Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28: 1413–1422
   PubMed Web of Science ®Google Scholar
• Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Dohner H, Schmitt M. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004; 108: 704–711
   PubMed Web of Science ®Google Scholar
• Chan L, Hardwick N, Darling D, Galea-Lauri J, Gaken J, Devereux S, Kemeny M, Mufti G, Farzaneh F. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 2005; 11: 120–131
   PubMed Web of Science ®Google Scholar
• Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, Wiesneth M, Dohner H, Schmitt M. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 2003; 120: 1000–1008
   PubMed Web of Science ®Google Scholar
• Carreno B M, Carter L L, Collins M. Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol 2005; 5: 424–430
   PubMed Web of Science ®Google Scholar
• Cheuk A T, Mufti G J, Guinn B A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004; 11: 215–226
   PubMed Web of Science ®Google Scholar
• Pollok K E, Kim Y J, Zhou Z, Hurtado J, Kim K K, Pickard R T, Kwon B S. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993; 150: 771–781
   PubMed Web of Science ®Google Scholar
• Turka L A, Ledbetter J A, Lee K, June C H, Thompson C B. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol 1990; 144: 1646–1653
   PubMed Web of Science ®Google Scholar
• Hurtado J C, Kim S H, Pollok K E, Lee Z H, Kwon B S. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995; 155: 3360–3367
   PubMed Web of Science ®Google Scholar
• Hurtado J C, Kim Y J, Kwon B S. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997; 158: 2600–2609
   PubMed Web of Science ®Google Scholar
• Guinn B A, DeBenedette M A, Watts T H, Berinstein N L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162: 5003–5010
   PubMed Web of Science ®Google Scholar
• Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol 1996; 26: 1851–1859
   PubMed Web of Science ®Google Scholar
• Chu N R, DeBenedette M A, Stiernholm B J, Barber B H, Watts T H. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells. J Immunol 1997; 158: 3081–3089
   PubMed Web of Science ®Google Scholar
• Greenberger J S, Sakakeeny M A, Humphries R K, Eaves C J, Eckner R J. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci USA 1983; 80: 2931–2935
   PubMed Web of Science ®Google Scholar
• Cheuk A T, Chan L, Czepulkowski B, Berger S A, Yagita H, Okumura K, Farzaneh F, Mufti G J, Guinn B A. Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother 2006; 55: 68–75
   PubMed Web of Science ®Google Scholar
• Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T, Matsuda H, Aoki T, Yagita H, Okumura K. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 2000; 191: 375–380
   PubMed Web of Science ®Google Scholar
• Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302
   PubMed Web of Science ®Google Scholar
• Martinet O, Divino C M, Zang Y, Gan Y, Mandeli J, Thung S, Pan P Y, Chen S H. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther 2002; 9: 786–792
   PubMed Web of Science ®Google Scholar
• Hu Q, Trevisan M, Xu Y, Dong W, Berger S A, Lyman S D, Minden M D. c-KIT expression enhances the leukemogenic potential of 32D cells. J Clin Invest 1995; 95: 2530–2538
   PubMed Web of Science ®Google Scholar
• Wilson J L, Charo J, Martin-Fontecha A, Dellabona P, Casorati G, Chambers B J, Kiessling R, Bejarano M T, Ljunggren H G. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 1999; 163: 4207–4212
   PubMed Web of Science ®Google Scholar
• Luque I, Reyburn H, Strominger J L. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol 2000; 61: 721–728
   PubMed Web of Science ®Google Scholar
• Azuma M, Cayabyab M, Buck D, Phillips J H, Lanier L L. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 1992; 149: 1115–1123
   PubMed Web of Science ®Google Scholar
• Chambers B J, Salcedo M, Ljunggren H G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996; 5: 311–317
   PubMed Web of Science ®Google Scholar
• Melero I, Johnston J V, Shufford W W, Mittler R S, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190: 167–172
   PubMed Web of Science ®Google Scholar
• Martinet O, Ermekova V, Qiao J Q, Sauter B, Mandeli J, Chen L, Chen S H. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst 2000; 92: 931–936
   PubMed Web of Science ®Google Scholar
• Chan L, Hardwick N R, Guinn B A, Darling D, Gaken J, Galea-Lauri J, Ho A Y, Mufti G J, Farzaneh F. An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 2006; 55: 1017–1024
   PubMed Web of Science ®Google Scholar